vs
Side-by-side financial comparison of STRATASYS LTD. (SSYS) and Vericel Corp (VCEL). Click either name above to swap in a different company.
STRATASYS LTD. is the larger business by last-quarter revenue ($137.0M vs $92.9M, roughly 1.5× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs -40.6%, a 65.6% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -2.2%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $2.5M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -7.4%).
Stratasys, Ltd. is an American-Israeli manufacturer of 3D printers, software, and materials for polymer additive manufacturing as well as 3D-printed parts on-demand. The company is incorporated in Israel. Engineers use Stratasys systems to model complex geometries in a wide range of polymer materials, including: ABS, polyphenylsulfone (PPSF), polycarbonate (PC), polyetherimide and Nylon 12.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
SSYS vs VCEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $137.0M | $92.9M |
| Net Profit | $-55.6M | $23.2M |
| Gross Margin | 41.0% | 78.7% |
| Operating Margin | -16.6% | 24.1% |
| Net Margin | -40.6% | 25.0% |
| Revenue YoY | -2.2% | 23.3% |
| Net Profit YoY | -109.0% | 17.3% |
| EPS (diluted) | — | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $92.9M | ||
| Q3 25 | $137.0M | $67.5M | ||
| Q2 25 | $138.1M | $63.2M | ||
| Q1 25 | $136.0M | $52.6M | ||
| Q4 24 | — | $75.4M | ||
| Q3 24 | $140.0M | $57.9M | ||
| Q2 24 | $138.0M | $52.7M | ||
| Q1 24 | $144.1M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $-55.6M | $5.1M | ||
| Q2 25 | $-16.7M | $-553.0K | ||
| Q1 25 | $-13.1M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $-26.6M | $-901.0K | ||
| Q2 24 | $-25.7M | $-4.7M | ||
| Q1 24 | $-26.0M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | 41.0% | 73.5% | ||
| Q2 25 | 43.1% | 73.7% | ||
| Q1 25 | 44.3% | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | 44.8% | 71.9% | ||
| Q2 24 | 43.8% | 69.5% | ||
| Q1 24 | 44.4% | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | -16.6% | 5.1% | ||
| Q2 25 | -12.0% | -3.2% | ||
| Q1 25 | -9.1% | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | -18.2% | -4.3% | ||
| Q2 24 | -18.9% | -11.5% | ||
| Q1 24 | -17.0% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | -40.6% | 7.5% | ||
| Q2 25 | -12.1% | -0.9% | ||
| Q1 25 | -9.6% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | -19.0% | -1.6% | ||
| Q2 24 | -18.6% | -8.9% | ||
| Q1 24 | -18.0% | -7.5% |
| Q4 25 | — | $0.46 | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $-0.23 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | — | $-0.10 | ||
| Q1 24 | — | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $71.5M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $852.5M | $354.6M |
| Total Assets | $1.1B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | $71.5M | $135.4M | ||
| Q2 25 | $71.1M | $116.9M | ||
| Q1 25 | $70.1M | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | $64.0M | $101.7M | ||
| Q2 24 | $70.9M | $102.5M | ||
| Q1 24 | $91.1M | $110.6M |
| Q4 25 | — | $354.6M | ||
| Q3 25 | $852.5M | $321.9M | ||
| Q2 25 | $902.4M | $306.8M | ||
| Q1 25 | $784.8M | $295.5M | ||
| Q4 24 | — | $292.0M | ||
| Q3 24 | $831.8M | $257.5M | ||
| Q2 24 | $850.5M | $243.0M | ||
| Q1 24 | $866.1M | $233.9M |
| Q4 25 | — | $488.0M | ||
| Q3 25 | $1.1B | $453.3M | ||
| Q2 25 | $1.1B | $435.6M | ||
| Q1 25 | $1.0B | $424.6M | ||
| Q4 24 | — | $432.7M | ||
| Q3 24 | $1.1B | $390.4M | ||
| Q2 24 | $1.1B | $376.8M | ||
| Q1 24 | $1.1B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.9M | $15.0M |
| Free Cash FlowOCF − Capex | $2.5M | $12.8M |
| FCF MarginFCF / Revenue | 1.8% | 13.8% |
| Capex IntensityCapex / Revenue | 3.2% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-11.5M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.0M | ||
| Q3 25 | $6.9M | $22.1M | ||
| Q2 25 | $-1.1M | $8.2M | ||
| Q1 25 | $4.5M | $6.6M | ||
| Q4 24 | — | $22.2M | ||
| Q3 24 | $-4.5M | $10.2M | ||
| Q2 24 | $-2.4M | $18.5M | ||
| Q1 24 | $7.3M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | $2.5M | $19.5M | ||
| Q2 25 | $-8.4M | $81.0K | ||
| Q1 25 | $789.0K | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | $-6.3M | $-9.2M | ||
| Q2 24 | $-4.9M | $1.8M | ||
| Q1 24 | $5.0M | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | 1.8% | 28.8% | ||
| Q2 25 | -6.1% | 0.1% | ||
| Q1 25 | 0.6% | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | -4.5% | -15.9% | ||
| Q2 24 | -3.6% | 3.4% | ||
| Q1 24 | 3.5% | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | 3.2% | 3.9% | ||
| Q2 25 | 5.3% | 12.9% | ||
| Q1 25 | 2.8% | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | 1.3% | 33.5% | ||
| Q2 24 | 1.8% | 31.8% | ||
| Q1 24 | 1.6% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSYS
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
